{"id":3367,"date":"2026-09-01T21:53:03","date_gmt":"2026-09-01T20:53:03","guid":{"rendered":"https:\/\/seamlessbio.de\/?p=3367"},"modified":"2026-09-01T21:53:06","modified_gmt":"2026-09-01T20:53:06","slug":"car-t-cell-expansion-hpl-vs-fbs","status":"publish","type":"post","link":"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/","title":{"rendered":"CAR-T Cell Expansion \u2014 hPL vs FBS"},"content":{"rendered":"<p><!--\nWORDPRESS BLOG POST\nSlug: car-t-cell-expansion-hpl-vs-fbs\nSEO Title: CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows | SeamlessBio\nMeta Description: A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\nFocus Keyword: CAR-T cell expansion hPL vs FBS\nAdditional Keywords: human platelet lysate CAR-T manufacturing, FBS vs hPL T cell expansion, xeno-free CAR-T medium, CAR-T ATMP manufacturing serum\nCategory: Cell Therapy \u00b7 ATMP \u00b7 CAR-T\n--><\/p>\n<style>\n.sb-bp{font-family:-apple-system,BlinkMacSystemFont,\"Segoe UI\",Roboto,sans-serif;max-width:780px;margin:0 auto;padding:0 0 60px;color:#202020;line-height:1.75}\n.sb-bp .lede{font-size:18px;font-weight:500;color:#3a4a50;border-left:4px solid #18b7b2;padding-left:20px;margin:0 0 32px;line-height:1.65}\n.sb-bp h2{font-size:24px;font-weight:800;margin:44px 0 14px;color:#111;padding-bottom:10px;border-bottom:2px solid #e2eceb}\n.sb-bp h3{font-size:18px;font-weight:700;margin:32px 0 10px;color:#18b7b2}\n.sb-bp p{margin:0 0 18px}\n.sb-bp ul,.sb-bp ol{margin:0 0 18px;padding-left:24px}\n.sb-bp li{margin-bottom:8px}\n.sb-bp table{width:100%;border-collapse:collapse;font-size:14px;margin:20px 0 28px;display:block;overflow-x:auto}\n.sb-bp th{background:#18b7b2;color:#fff;text-align:left;padding:10px 14px;font-weight:700;white-space:nowrap}\n.sb-bp td{padding:10px 14px;border-bottom:1px solid #e2eceb;vertical-align:top}\n.sb-bp tr:last-child td{border-bottom:none}\n.sb-bp td:first-child{font-weight:600;color:#111}\n.sb-bp a{color:#18b7b2;text-decoration:none;font-weight:600}\n.sb-bp strong{color:#111}\n.sb-bp .box{background:#f1faf9;border-left:4px solid #18b7b2;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .warn{background:#fff8e1;border-left:4px solid #f59e0b;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .cta-box{background:linear-gradient(135deg,#e4f6f5,#f4fbfb);border:1px solid rgba(24,183,178,.2);border-radius:16px;padding:28px;margin-top:44px;text-align:center}\n.sb-bp .cta-box h3{color:#111;margin:0 0 10px;font-size:20px}\n.sb-bp .cta-box p{color:#5b6b71;margin:0 0 18px}\n.sb-bp .cta-btns{display:flex;justify-content:center;gap:12px;flex-wrap:wrap}\n.sb-bp .btn{display:inline-block;background:#18b7b2;color:#fff!important;padding:10px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n.sb-bp .btn-o{display:inline-block;border:2px solid #18b7b2;color:#18b7b2!important;padding:8px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n<\/style>\n<div class=\"sb-bp\">\n<p class=\"lede\">The shift from FBS to human platelet lysate (hPL) in CAR-T cell manufacturing is no longer a regulatory preference \u2014 it is becoming the de facto standard for clinical-grade production. But the decision is not purely regulatory. There is a growing body of published data showing that hPL-expanded T cells are functionally different from FBS-expanded T cells in ways that matter for therapeutic efficacy. This post reviews what the data shows.<\/p>\n<h2>Why the serum source matters for T cell biology<\/h2>\n<p>T cells are exquisitely sensitive to the cytokine and growth factor environment during ex vivo expansion. The serum supplement is not merely a nutrient source \u2014 it is a complex biological signal that shapes T cell phenotype, exhaustion status, memory differentiation, and ultimately in vivo persistence after infusion. Two serum sources that look similar on a CoA can produce T cells with fundamentally different functional profiles.<\/p>\n<p>FBS provides bovine growth factors \u2014 IGF-1, TGF-\u03b2, PDGF, EGF \u2014 that are not species-matched for human T cell receptors. Human platelet lysate provides human-sequence equivalents of these factors, released from platelet alpha granules during freeze-thaw lysis. For human T cells, species-matched growth factors are more potent at lower concentrations \u2014 meaning hPL at 5% can drive faster expansion than FBS at 10%.<\/p>\n<h2>The published data \u2014 expansion rate<\/h2>\n<p>Multiple published studies have compared FBS and hPL for primary human T cell and CAR-T expansion. The consistent finding:<\/p>\n<table>\n<thead>\n<tr>\n<th>Study parameter<\/th>\n<th>FBS (10%)<\/th>\n<th>hPL (5%)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Expansion fold (14 days)<\/td>\n<td>100\u2013300\u00d7<\/td>\n<td>300\u20131,000\u00d7<\/td>\n<\/tr>\n<tr>\n<td>Population doubling time<\/td>\n<td>18\u201324h<\/td>\n<td>14\u201320h<\/td>\n<\/tr>\n<tr>\n<td>Cell viability<\/td>\n<td>85\u201395%<\/td>\n<td>90\u201397%<\/td>\n<\/tr>\n<tr>\n<td>CD4:CD8 ratio maintenance<\/td>\n<td>Variable \u2014 lot-dependent<\/td>\n<td>More stable across hPL lots<\/td>\n<\/tr>\n<tr>\n<td>CD3+ purity post-expansion<\/td>\n<td>Comparable<\/td>\n<td>Comparable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The higher expansion rate in hPL is primarily driven by higher concentrations of human PDGF-AB\/BB and EGF released from platelet alpha granules \u2014 both of which signal through receptors expressed on activated T cells and drive proliferation more effectively than their bovine equivalents in FBS.<\/p>\n<h2>The critical difference \u2014 T cell phenotype and exhaustion<\/h2>\n<p>Expansion rate alone is not the relevant metric for CAR-T manufacturing. What matters is the phenotype of the expanded cells \u2014 specifically the memory differentiation status and exhaustion marker expression, which directly predict in vivo persistence and therapeutic efficacy after infusion.<\/p>\n<p>T cell memory differentiation follows a hierarchy: na\u00efve (Tnaive) \u2192 stem cell memory (Tscm) \u2192 central memory (Tcm) \u2192 effector memory (Tem) \u2192 terminally differentiated effector (Teff). Less differentiated cells (Tscm, Tcm) persist longer in vivo and are associated with superior clinical responses in CAR-T therapy. More differentiated cells (Tem, Teff) expand rapidly in vitro but exhaust quickly after infusion.<\/p>\n<table>\n<thead>\n<tr>\n<th>Phenotype marker<\/th>\n<th>FBS-expanded T cells<\/th>\n<th>hPL-expanded T cells<\/th>\n<th>Clinical relevance<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>CD62L+ (central memory)<\/td>\n<td>Lower \u2014 more differentiated<\/td>\n<td>Higher \u2014 less differentiated<\/td>\n<td>Higher CD62L \u2192 better in vivo persistence<\/td>\n<\/tr>\n<tr>\n<td>CCR7+ (lymph node homing)<\/td>\n<td>Nach unten<\/td>\n<td>H\u00f6her<\/td>\n<td>Higher CCR7 \u2192 better tissue trafficking<\/td>\n<\/tr>\n<tr>\n<td>PD-1 (exhaustion marker)<\/td>\n<td>Higher expression<\/td>\n<td>Lower expression<\/td>\n<td>Lower PD-1 \u2192 less exhaustion, better activity<\/td>\n<\/tr>\n<tr>\n<td>TIM-3 (exhaustion marker)<\/td>\n<td>Higher expression<\/td>\n<td>Lower expression<\/td>\n<td>Lower TIM-3 \u2192 longer functional lifespan<\/td>\n<\/tr>\n<tr>\n<td>LAG-3 (exhaustion marker)<\/td>\n<td>Higher expression<\/td>\n<td>Lower expression<\/td>\n<td>Lower LAG-3 \u2192 reduced co-inhibitory signalling<\/td>\n<\/tr>\n<tr>\n<td>Ki-67 (proliferation)<\/td>\n<td>Lower at day 14<\/td>\n<td>Higher at day 14<\/td>\n<td>More proliferative cells \u2192 better engraftment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"box\">\n<strong>The key finding:<\/strong> FBS-expanded T cells show higher exhaustion marker expression (PD-1, TIM-3, LAG-3) and lower central memory frequency (CD62L+, CCR7+) compared to hPL-expanded T cells from the same donor. This is consistent across multiple independent studies and is attributed to TGF-\u03b2 signalling \u2014 bovine TGF-\u03b2 in FBS is more potent at driving T cell differentiation toward an exhausted phenotype than human TGF-\u03b2 equivalents in hPL.\n<\/div>\n<h2>CAR-T specific considerations<\/h2>\n<p>For CAR-T cells specifically (as opposed to polyclonal T cell therapies), the serum source affects not only the non-transduced T cell expansion but also the transduction efficiency of the lentiviral or retroviral vector used to introduce the CAR construct:<\/p>\n<ul>\n<li><strong>Lentiviral transduction efficiency:<\/strong> hPL-expanded T cells show comparable or higher lentiviral transduction efficiency compared to FBS-expanded cells \u2014 despite faster proliferation (which can dilute the integrated provirus). The higher viability of hPL-expanded cells at the time of transduction may account for this<\/li>\n<li><strong>CAR expression stability:<\/strong> CAR expression levels (measured by CAR surface density and MFI) are comparable between FBS and hPL conditions post-transduction<\/li>\n<li><strong>Cytotoxic function:<\/strong> hPL-expanded CAR-T cells show equivalent or superior target cell killing in co-culture assays, consistent with lower exhaustion marker expression<\/li>\n<\/ul>\n<h2>Regulatory considerations \u2014 why hPL is increasingly mandatory<\/h2>\n<p>EMA Advanced Therapy Guidelines (EMA\/CAT\/CPWP\/573420\/2023) strongly encourage elimination of xenogenic (animal-derived) components from ATMP manufacturing processes. FBS introduces:<\/p>\n<ul>\n<li>TSE\/BSE risk requiring country-of-origin certification and lot-specific documentation<\/li>\n<li>Adventitious agent risk (BVDV, other bovine viruses) requiring testing per lot<\/li>\n<li>Potential bovine protein immunogenicity in the final cell product (residual FBS proteins adsorbed to T cell surfaces)<\/li>\n<li>Lot-to-lot variability that complicates process consistency demonstration in the IND\/CTA<\/li>\n<\/ul>\n<p>Human platelet lysate, collected from screened human donors with IRB clearance and full documentation, eliminates all bovine-specific risks and simplifies the ATMP raw material risk assessment significantly.<\/p>\n<h2>Practical implementation \u2014 switching from FBS to hPL<\/h2>\n<p>The transition from FBS to hPL for T cell expansion is straightforward but requires attention to two specific issues:<\/p>\n<p><strong>1. Fibrinogen:<\/strong> hPL contains fibrinogen at 2\u20134 mg\/mL \u2014 at body temperature in T cell culture medium, fibrinogen can form a gel that interferes with T cell suspension culture. Add heparin at 2 IU\/mL to prevent fibrin gel formation. Alternatively, use fibrinogen-depleted hPL formulations.<\/p>\n<p><strong>2. Concentration:<\/strong> hPL at 5% is typically sufficient \u2014 higher concentrations (7.5\u201310%) may be used in the first 48\u201372 hours post-activation but are usually not needed throughout the expansion. The higher growth factor density in hPL means that 5% hPL typically outperforms 10% FBS, making it cost-neutral despite the higher per-mL price of hPL.<\/p>\n<div class=\"cta-box\">\n<h3>Human Platelet Lysate for CAR-T and T Cell Expansion<\/h3>\n<p>SeamlessBio supplies GMP-compatible human platelet lysate (hPL) \u2014 xeno-free, full donor documentation, IRB clearance, available in research and GMP grade. Quote within 48 hours.<\/p>\n<div class=\"cta-btns\">\n<a href=\"https:\/\/seamlessbio.de\/de\/menschliches-thrombozytenlysat\/\" class=\"btn-o\">Lysat aus menschlichen Blutpl\u00e4ttchen (hPL) \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-human-platelet-lysate-hpl\/\" class=\"btn-o\">What is hPL? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/ressourcen\/blog\/human-platelet-lysate-hpl-fbs-replacement-guide\/\" class=\"btn-o\">hPL Complete Guide \u2014 Replacing FBS \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-atmp\/\" class=\"btn-o\">What is ATMP? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-xeno-free-cell-culture\/\" class=\"btn-o\">What is Xeno-Free Cell Culture? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\" class=\"btn-o\">Request hPL Sample \u2192<\/a>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The shift from FBS to human platelet lysate (hPL) in CAR-T cell manufacturing is no longer a regulatory preference \u2014 it is becoming the de facto standard for clinical-grade production. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-3367","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows<\/title>\n<meta name=\"description\" content=\"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows\" \/>\n<meta property=\"og:description\" content=\"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T20:53:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T20:53:06+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\"},\"headline\":\"CAR-T Cell Expansion \u2014 hPL vs FBS\",\"datePublished\":\"2026-09-01T20:53:03+00:00\",\"dateModified\":\"2026-09-01T20:53:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\"},\"wordCount\":962,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\",\"name\":\"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-09-01T20:53:03+00:00\",\"dateModified\":\"2026-09-01T20:53:06+00:00\",\"description\":\"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\",\"ProfessionalService\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-organization-logo\"},\"address\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-place-address\"},\"telephone\":[\"+49 (851) 37932226\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+49 (851) 37932226\",\"email\":\"info@seamlessbio.de\"},\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"},{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Saturday\",\"Sunday\"],\"opens\":\"00:00\",\"closes\":\"00:00\"}],\"email\":\"info@seamlessbio.de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/seamlessbio.de\"],\"url\":\"https:\\\/\\\/seamlessbio.de\\\/de\\\/author\\\/admin\\\/\"},{\"@type\":\"PostalAddress\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-place-address\",\"streetAddress\":\"Dr.-Ernst-Derra-Str. 4\",\"addressLocality\":\"Passau\",\"postalCode\":\"94036\",\"addressRegion\":\"Bavaria\",\"addressCountry\":\"DE\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"width\":973,\"height\":288,\"caption\":\"SeamlessBio\"}]}<\/script>\n<meta name=\"geo.placename\" content=\"Passau\" \/>\n<meta name=\"geo.region\" content=\"Deutschland\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows","description":"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/","og_locale":"de_DE","og_type":"article","og_title":"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows","og_description":"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.","og_url":"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/","og_site_name":"SeamlessBio","article_published_time":"2026-09-01T20:53:03+00:00","article_modified_time":"2026-09-01T20:53:06+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"admin","Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#article","isPartOf":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/"},"author":{"name":"admin","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529"},"headline":"CAR-T Cell Expansion \u2014 hPL vs FBS","datePublished":"2026-09-01T20:53:03+00:00","dateModified":"2026-09-01T20:53:06+00:00","mainEntityOfPage":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/"},"wordCount":962,"commentCount":0,"publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/","url":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/","name":"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-09-01T20:53:03+00:00","dateModified":"2026-09-01T20:53:06+00:00","description":"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/"]}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place","ProfessionalService"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-organization-logo"},"address":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-place-address"},"telephone":["+49 (851) 37932226"],"contactPoint":{"@type":"ContactPoint","telephone":"+49 (851) 37932226","email":"info@seamlessbio.de"},"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday"],"opens":"09:00","closes":"17:00"},{"@type":"OpeningHoursSpecification","dayOfWeek":["Saturday","Sunday"],"opens":"00:00","closes":"00:00"}],"email":"info@seamlessbio.de"},{"@type":"Person","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529","name":"admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/seamlessbio.de"],"url":"https:\/\/seamlessbio.de\/de\/author\/admin\/"},{"@type":"PostalAddress","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-place-address","streetAddress":"Dr.-Ernst-Derra-Str. 4","addressLocality":"Passau","postalCode":"94036","addressRegion":"Bavaria","addressCountry":"DE"},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","width":973,"height":288,"caption":"SeamlessBio"}]},"geo.placename":"Passau","geo.region":"Deutschland"},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=3367"}],"version-history":[{"count":1,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3367\/revisions"}],"predecessor-version":[{"id":3368,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3367\/revisions\/3368"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=3367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/categories?post=3367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/tags?post=3367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}